Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)

• Published in: Scientific reports Vol. 9; no. 1; pp. 20081 - 12
• Main Authors: Lopez-Tarruella, Sara, Escudero, M. J., Pollan, Marina, Martín, Miguel, Jara, Carlos, Bermejo, Begoña, Guerrero-Zotano, Angel, García-Saenz, José, Santaballa, Ana, Alba, Emilio, Andrés, Raquel, Martínez, Purificación, Calvo, Lourdes, Fernández, Antonio, Batista, Norberto, Llombart-Cussac, Antonio, Antón, Antonio, Lahuerta, Ainhara, de la Haba, Juan, López-Vega, José Manuel, Carrasco, E.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 27.12.2019; Nature Publishing Group
• Subjects: 692/4028/67/1347; 692/4028/67/2324; Aged; Bone surgery; Bone tumors; Breast cancer; Breast Neoplasms - epidemiology; Breast Neoplasms - pathology; Breast Neoplasms - surgery; Clinical trials; Female; Humanities and Social Sciences; Humans; Metastases; Metastasis; Middle Aged; multidisciplinary; Neoplasm Metastasis; Registries; Retrospective Studies; Science; Science (multidisciplinary); Spain - epidemiology; Statistical analysis; Surgery; Survival; Tumors; Viscera; Spain
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-019-55765-9

The debate about surgical resection of primary tumor (PT) in de novo metastatic breast cancer (MBC) patients persists. We explored this approach’s outcomes in patients included in a retrospective registry, named El Álamo , of breast cancer patients diagnosed in Spain (1990–2001). In this analysis we only included de novo MBC patients, 1415 of whom met the study’s criteria. Descriptive, Kaplan-Meier and Cox regression analyses were carried out. Median age was 63.1 years, 49.2% of patients had single-organ metastasis (skin/soft tissue [16.3%], bone [33.8%], or viscera [48.3%]). PT surgery (S) was performed in 44.5% of the cases. S-group patients were younger, had smaller tumors, higher prevalence of bone and oligometastatic disease, and lower prevalence of visceral involvement. With a median follow-up of 23.3 months, overall survival (OS) was 39.6 versus 22.4 months (HR = 0.59, p < 0.0001) in the S- and non-S groups, respectively. The S-group OS benefit remained statistically and clinically significant regardless of metastatic location, histological type, histological grade, hormone receptor status and tumor size. PT surgery (versus no surgery) was associated with an OS benefit suggesting that loco-regional PT control may be considered in selected MBC patients. Data from randomized controlled trials are of utmost importance to confirm these results.